Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Steno Diabetes Center Bayer |
---|---|
Information provided by: | Steno Diabetes Center |
ClinicalTrials.gov Identifier: | NCT00311870 |
The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months
Condition | Intervention | Phase |
---|---|---|
Diabetic Nephropathy |
Drug: nisoldipine Drug: lisinopril |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study |
Estimated Enrollment: | 52 |
Study Start Date: | March 1993 |
Estimated Study Completion Date: | April 1999 |
-
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Denmark | |
Steno Diabetes Center | |
Gentofte, Denmark, DK-2820 |
Principal Investigator: | Peter Rossing, MD | Steno Diabetes Center |
Study Chair: | Hans-Henrik Parving, MD | Steno Diabetes Center |
Study ID Numbers: | KA 92126 |
Study First Received: | April 4, 2006 |
Last Updated: | April 4, 2006 |
ClinicalTrials.gov Identifier: | NCT00311870 History of Changes |
Health Authority: | Denmark: Ethics Committee; Denmark: Danish Medicines Agency |
Vasodilator Agents Nisoldipine Diabetic Nephropathies Lisinopril Diabetes Mellitus Endocrine System Diseases Calcium Channel Blockers Cardiovascular Agents |
Antihypertensive Agents Protease Inhibitors Calcium, Dietary Urologic Diseases Angiotensin-Converting Enzyme Inhibitors Kidney Diseases Endocrinopathy Diabetes Complications |
Vasodilator Agents Nisoldipine Diabetic Nephropathies Molecular Mechanisms of Pharmacological Action Cardiotonic Agents Physiological Effects of Drugs Lisinopril Diabetes Mellitus Endocrine System Diseases Calcium Channel Blockers Enzyme Inhibitors |
Cardiovascular Agents Antihypertensive Agents Protective Agents Pharmacologic Actions Protease Inhibitors Membrane Transport Modulators Urologic Diseases Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Kidney Diseases Diabetes Complications |